This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Baxter Receives 510(k) Clearance For Next-Generation SIGMA Spectrum Infusion Pump With Master Drug Library

Stocks in this article: BAX

Baxter International Inc. (NYSE:BAX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation SIGMA Spectrum Infusion Pump with Master Drug Library. Enhancements to the infusion pump include increased capacity of the master drug library, which is safety software that enables a hospital to maintain a customized in-house library of facility-defined dosing parameters for infusions to minimize the likelihood of drug errors during care. In addition, new asset-tracking capabilities will allow hospitals to effectively locate, manage and deploy SIGMA Spectrum inventory, helping to ensure efficient allocation of hospital assets.

Baxter plans to launch the next-generation SIGMA Spectrum with select healthcare facilities beginning in the summer of 2014.

''Clinicians are looking for integrated systems that are efficient and cost effective, and allow hospital staff to focus on providing quality care for patients,'' said Brik Eyre, president of Baxter’s Hospital Products business. ''We are excited to bring the next generation of Baxter’s SIGMA Spectrum Infusion Pump with Master Drug Library and its advanced, patient-centered safety technology to the U.S. marketplace.''

Infusion pumps are used throughout hospitals and other acute and chronic care settings to deliver fluids and medications that save and sustain lives. Baxter’s SIGMA Spectrum Infusion Pump with Master Drug Library provides multiple safety features, including dose error reduction software (DERS) and an automatic default to use of the drug safety library at the initial start of dose programming. It also offers an option for wireless connectivity to integrate data into a hospital's electronic medical record (EMR) system, to facilitate the transfer of data to and from the system for updating drug libraries, and to create continuous quality improvement reports.

The 510(k) clearance of Baxter’s next-generation SIGMA Spectrum Infusion Pump with Master Drug Library builds on the past success of the pump platform, a three-consecutive-year winner of the ''Best in KLAS'' award for Smart Pumps – LVP 1 in the Best in KLAS Awards: Medical Equipment & Infrastructure Report from 2011 – 2013. The SIGMA Spectrum Infusion System is used in four of U.S. News & World Report’s 2013-2014 top seven ranked hospitals. Baxter will continue to service SIGMA Spectrum pumps currently in the field.

About Baxter

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,862.72 +84.57 0.48%
S&P 500 2,075.33 +14.10 0.68%
NASDAQ 4,775.7190 +27.3230 0.58%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs